Strs Ohio increased its stake in shares of Cepheid (NASDAQ:CPHD) by 22.3% during the second quarter, Holdings Channel reports. The institutional investor owned 42,800 shares of the company’s stock after buying an additional 7,800 shares during the period. Strs Ohio’s holdings in Cepheid were worth $1,316,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the stock. Norges Bank acquired a new position in shares of Cepheid during the fourth quarter valued at about $32,233,000. Granahan Investment Management Inc. MA increased its stake in Cepheid by 63.6% in the first quarter. Granahan Investment Management Inc. MA now owns 847,900 shares of the company’s stock worth $28,286,000 after buying an additional 329,500 shares during the last quarter. Eagle Asset Management Inc. purchased a new stake in Cepheid during the second quarter worth $8,586,000. Bogle Investment Management L P DE purchased a new stake in Cepheid during the first quarter worth $7,096,000. Finally, Canada Pension Plan Investment Board increased its stake in Cepheid by 83.6% in the first quarter. Canada Pension Plan Investment Board now owns 291,500 shares of the company’s stock worth $9,724,000 after buying an additional 132,700 shares during the last quarter. 95.27% of the stock is currently owned by institutional investors and hedge funds.
Shares of Cepheid (NASDAQ:CPHD) traded down 0.17% on Tuesday, reaching $52.75. The company had a trading volume of 1,497,141 shares. The stock’s market cap is $3.85 billion. The stock has a 50-day moving average price of $47.54 and a 200-day moving average price of $35.72. Cepheid has a 12 month low of $25.09 and a 12 month high of $53.91.
Cepheid (NASDAQ:CPHD) last announced its earnings results on Thursday, July 28th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.19. The business earned $146 million during the quarter, compared to analyst estimates of $145.82 million. Cepheid had a negative return on equity of 10.20% and a negative net margin of 8.78%. Cepheid’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the company earned ($0.06) EPS. Analysts predict that Cepheid will post $0.33 earnings per share for the current fiscal year.
A number of research firms have recently weighed in on CPHD. Canaccord Genuity restated a “hold” rating and set a $32.00 target price on shares of Cepheid in a research report on Wednesday, June 29th. Zacks Investment Research downgraded Cepheid from a “buy” rating to a “hold” rating in a research report on Wednesday, June 29th. Craig Hallum downgraded Cepheid from a “buy” rating to a “hold” rating in a research report on Tuesday, September 6th. TheStreet upgraded Cepheid from a “sell” rating to a “hold” rating in a research report on Wednesday, September 28th. Finally, Citigroup Inc. downgraded Cepheid from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $44.00 to $53.00 in a research report on Thursday, September 8th. Seventeen investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $41.83.
In other news, VP Scott A. Campbell sold 746 shares of Cepheid stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $36.71, for a total value of $27,385.66. Following the completion of the transaction, the vice president now directly owns 10,721 shares of the company’s stock, valued at approximately $393,567.91. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.16% of the company’s stock.
Cepheid Company Profile
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Want to see what other hedge funds are holding CPHD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cepheid (NASDAQ:CPHD).
Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.